Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib in Unresectable Hepatocellular Carcinoma
NCT04297254Phase 4Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Eisai Co., Ltd. Primary endpoints: Percentage of Participants with Grade 3 or Higher Treatment-emergent Adverse Events, Number of Participants with Serious Adverse Events and 1 more. Started Feb 2021; status: completed.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04297254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04297254.